Spiriva®
Tiotropium is a long-acting muscarinic antagonist (LAMA) for maintenance treatment of COPD and asthma. Provides 24-hour bronchodilation.
| Dosage Form | Inhaler (DPI HandiHaler / Soft Mist Respimat) |
| Strength | 18 mcg capsule (DPI); 1.25 mcg, 2.5 mcg per actuation (Respimat) |
| Storage | Store at 25°C. Do not expose capsules to extreme temperatures/moisture. |
| Category | Respiratory |
| Availability | Available for Transfer |
COPD (maintenance to reduce exacerbations); asthma (add-on maintenance, ≥6 years).
Quaternary ammonium compound that selectively blocks M3 muscarinic receptors in airway smooth muscle. Dissociates very slowly from M3 receptors, providing prolonged bronchodilation.
Each Burrard Pharmaceuticals technology transfer package for Tiotropium includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier templates — available through Burrard Intelligence subscription.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Our team can deliver the complete know-how package within 2–21 business days. Book a consultation to discuss your specific requirements.